The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already current for the therapy of anemia in grownup patients with beta thalassemia who require crimson blood…
The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already current for the therapy of anemia in grownup patients with beta thalassemia who require crimson blood…